CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine..

中国成都，2024年5月10日/PRNewswire/--WestGene，一家致力于mRNA技术的生物技术公司，宣布了其mRNA治疗性癌症疫苗WGc-043获得FDA IND批准的历史性里程碑。这一里程碑式的成就标志着世界上首次批准了与EB病毒相关的mRNA治疗性癌症疫苗。。

Continue Reading

继续阅读

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

WestGene的mRNA治疗性癌症疫苗获得FDA批准

Founded by renowned Dr. Yuquan Wei, Academician of the Chinese Academy of Sciences, and Dr. Xiangrong Song, WestGene has become a driving force in mRNA technology research and innovative drug development. With a relentless pursuit of scientific excellence, WestGene's latest milestone underscores its commitment to advancing the frontiers of biomedicine..

WestGene由著名的中国科学院院士魏玉泉博士和宋向荣博士创立，已成为mRNA技术研究和创新药物开发的驱动力。凭借对科学卓越的不懈追求，WestGene的最新里程碑强调了其对推进生物医学前沿的承诺。。

The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers. EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

FDA对WGc-043的批准代表了癌症治疗的重大进展，为晚期EB病毒相关癌症患者提供了新的希望。EB病毒与十多种恶性肿瘤高度相关，包括鼻咽癌（NPC），自然杀伤T细胞淋巴瘤（NKTL），胃癌，肺癌，肝癌，食道癌，乳腺癌，宫颈癌以及自身免疫性疾病，如多发性硬化症和系统性红斑狼疮。

These are potential indications for WGc-043..

这些是WGc-043的潜在适应症。。

WGc-043 shows promising efficacy, low toxicity, broad applicability, efficient scalability, and cost effectiveness. WGc-043 has already completed investigator-initiated trials (IIT) in NPC and NKTL, demonstrating superior safety and efficacy compared to other publicly available mRNA therapeutic cancer vaccines.

WGc-043显示出有希望的功效，低毒性，广泛的适用性，有效的可扩展性和成本效益。WGc-043已经在NPC和NKTL中完成了研究者发起的试验（IIT），与其他公开可用的mRNA治疗癌症疫苗相比，表现出更高的安全性和有效性。

Once successfully launched, WGc-043 will provide a new treatment option for patients with advanced EB virus-positive solid tumors and hematologic malignancies.As WestGene moves forward, its strategic focus on global collaboration underscores its vision for commercial expansion and market penetration.

一旦成功推出，WGc-043将为晚期EB病毒阳性实体瘤和血液系统恶性肿瘤患者提供新的治疗选择。随着WestGene的发展，其全球合作的战略重点突出了其商业扩张和市场渗透的愿景。

With a diverse pipeline of over 20 mRNA-based therapeutic products targeting a spectrum of diseases, WestGene is poised to reshape the biopharmaceutical landscape. WestGene has made significant breakthroughs in the three key technologies of mRNA drug development: mRNA sequence design, delivery vectors, and manufacturing.

凭借针对多种疾病的20多种基于mRNA的治疗产品，WestGene有望重塑生物制药领域。WestGene在mRNA药物开发的三项关键技术：mRNA序列设计，递送载体和制造方面取得了重大突破。

And the patent for ionizable lipids has been granted in countries and regions such as China, the United States and Europe.The FDA approval of WGc-043 marks a turning point in the fight against cancers and underscores WestGene's commitment to mRNA technology. As WestGene continues to push the boundaries of scientific discovery, its pioneering spirit promises to open new frontiers in cancer therapy and beyond.Photo - https://mma.prnewswire.com/media/2409488/WestGene_s_mRNA_Therapeutic_Cancer_Vaccine_Receives_FDA_Approval.jpg.

可电离脂质的专利已在中国、美国和欧洲等国家和地区获得批准。FDA批准WGc-043标志着抗癌斗争的转折点，并强调了WestGene对mRNA技术的承诺。随着WestGene不断突破科学发现的界限，其开拓精神有望在癌症治疗及其他领域开辟新的前沿。照片-https://mma.prnewswire.com/media/2409488/WestGene_s_mRNA_Therapeutic_Cancer_Vaccine_Receives_FDA_Approval.jpg.